AI Stock Finder
Loading...
Skip to main content
Model output · Signal date Oct. 16, 2026

Daily Signals

2697 companies scored · 2026-10-16 run in progress: 19 of ~5380 signals so far · Alpha · vs marketSwitch to Total · 30D 90D

Signal date 2026-10-16 Cut-offs from the 2026-10-15 run
Companies scored 2697 IC ≥ 0 · market cap ≥ $100M
Median forecast -0.28% Alpha · 90D
Long–short spread +5.09% Strong Buy minus Strong Sell, mean
Median IC 0.28 Spearman · 90D
Rating changes ▲ 552 ▼ 703 vs the previous run
Cross-section

Distribution of the day's forecasts

90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).

Signals · All

304 companies

Sorted by market cap ↓ · forecast rankings are part of the paid plans

# Ticker Sector IC Mkt cap Rating 30D 90D Δ
201 SGMTSagimet Biosciences Inc. Life Sciences 0.35 $469M Unlock rating and forecasts
202 ARVNARVINAS, INC. Life Sciences 0.25 $468M Unlock rating and forecasts
203 ALLOAllogene Therapeutics, Inc. Life Sciences 0.05 $463M Unlock rating and forecasts
204 AUTLAutolus Therapeutics plc Life Sciences 0.32 $458M Neutral -0.09% -0.14% ▼ 2
205 RGNXREGENXBIO Inc. Life Sciences 0.03 $454M Unlock rating and forecasts
206 NGNENeurogene Inc. Life Sciences 0.03 $444M Unlock rating and forecasts
207 PROKPROKIDNEY CORP. Life Sciences 0.00 $442M Unlock rating and forecasts
208 ENTXEntera Bio Ltd. Life Sciences 0.26 $433M Unlock rating and forecasts
209 NIKANIKA PHARMACEUTICALS, INC Life Sciences 0.17 $431M Unlock rating and forecasts
210 PRTAPROTHENA CORP PUBLIC LTD CO Life Sciences 0.27 $430M Unlock rating and forecasts
211 OVIDOvid Therapeutics Inc. Life Sciences 0.07 $428M Unlock rating and forecasts
212 TLRYTilray Brands, Inc. Life Sciences 0.01 $428M Neutral -0.20% -0.79% ▲ 1
213 CAPRCAPRICOR THERAPEUTICS, INC. Life Sciences 0.44 $423M Unlock rating and forecasts
214 ZURAZura Bio Ltd Life Sciences 0.24 $423M Unlock rating and forecasts
215 ASMBASSEMBLY BIOSCIENCES, INC. Life Sciences 0.06 $419M Unlock rating and forecasts
216 TKNOAlpha Teknova, Inc. Life Sciences 0.46 $418M Unlock rating and forecasts
217 TECXTectonic Therapeutic, Inc. Life Sciences 0.02 $410M Unlock rating and forecasts
218 EIKNEikon Therapeutics, Inc. Life Sciences 0.32 $408M Unlock rating and forecasts
219 MYGNMYRIAD GENETICS INC Life Sciences 0.39 $397M Unlock rating and forecasts
220 ADXNAddex Therapeutics Ltd. Life Sciences 0.02 $392M Unlock rating and forecasts
221 SPRYARS Pharmaceuticals, Inc. Life Sciences 0.25 $391M Neutral +0.99% +0.06% ·
222 CANFCan-Fite BioPharma Ltd. Life Sciences 0.17 $383M Unlock rating and forecasts
223 EDITEditas Medicine, Inc. Life Sciences 0.21 $375M Unlock rating and forecasts
224 EBSEmergent BioSolutions Inc. Life Sciences 0.55 $368M Unlock rating and forecasts
225 GALTGALECTIN THERAPEUTICS INC Life Sciences 0.07 $367M Neutral +0.22% -0.26% ·
226 FENCFENNEC PHARMACEUTICALS INC. Life Sciences 0.35 $363M Unlock rating and forecasts
227 KYTXKyverna Therapeutics, Inc. Life Sciences 0.62 $352M Unlock rating and forecasts
228 RLMDRELMADA THERAPEUTICS, INC. Life Sciences 0.36 $346M Unlock rating and forecasts
229 PRLDPrelude Therapeutics Inc Life Sciences 0.03 $343M Unlock rating and forecasts
230 CCCCC4 Therapeutics, Inc. Life Sciences 0.31 $342M Unlock rating and forecasts
231 IRDOpus Genetics, Inc. Life Sciences 0.30 $341M Unlock rating and forecasts
232 ENTAENANTA PHARMACEUTICALS INC Life Sciences 0.52 $334M Unlock rating and forecasts
233 IKTInhibikase Therapeutics, Inc. Life Sciences 0.07 $328M Unlock rating and forecasts
234 CYPHCYPHERPUNK TECHNOLOGIES INC. Life Sciences 0.17 $325M Neutral 0.00% +0.04% ·
235 ARCTArcturus Therapeutics Holdings Inc. Life Sciences 0.17 $320M Unlock rating and forecasts
236 TTRXTurn Therapeutics Inc. Life Sciences 0.71 $316M Unlock rating and forecasts
237 AGENAGENUS INC Life Sciences 0.59 $301M Unlock rating and forecasts
238 ARTVArtiva Biotherapeutics, Inc. Life Sciences 0.23 $296M Unlock rating and forecasts
239 OCGNOcugen, Inc. Life Sciences 0.42 $285M Unlock rating and forecasts
240 USNAUSANA HEALTH SCIENCES INC Life Sciences 0.59 $282M Unlock rating and forecasts
241 FULCFulcrum Therapeutics, Inc. Life Sciences 0.01 $280M Unlock rating and forecasts
242 SRZNSurrozen, Inc./DE Life Sciences 0.01 $279M Unlock rating and forecasts
243 NWBONORTHWEST BIOTHERAPEUTICS INC Life Sciences 0.00 $270M Neutral -0.07% -0.32% ·
244 ELTPELITE PHARMACEUTICALS INC /NV/ Life Sciences 0.35 $267M Unlock rating and forecasts
245 CATXPerspective Therapeutics, Inc. Life Sciences 0.11 $267M Unlock rating and forecasts
246 PALIPALISADE BIO, INC. Life Sciences 0.13 $265M Unlock rating and forecasts
247 CABACabaletta Bio, Inc. Life Sciences 0.05 $263M Unlock rating and forecasts
248 ACBAURORA CANNABIS INC Life Sciences 0.17 $260M Neutral +0.07% +0.16% ·
249 VNDAVanda Pharmaceuticals Inc. Life Sciences 0.39 $255M Unlock rating and forecasts
250 ABEOABEONA THERAPEUTICS INC. Life Sciences 0.09 $252M Unlock rating and forecasts
201–250 of 304 Previous Next
Since the previous run

Rating changes

▲ 552▼ 703
Which companies were upgraded or downgraded is part of the paid plans.
Next step

Unlock the full ranking

Every company's rating, its 30- and 90-day forecasts, the forecast and IC-weighted rankings, the daily rating changes and CSV export.

See plans Create a free account
Methodology

Ratings are relative: the forecasts of the latest complete daily run (2026-10-15) are ranked and cut at the 15th, 35th, 65th and 85th percentiles, so Strong Sell is the bottom 15%, Sell the next 20%, Neutral the middle 30%, Buy the next 20% and Strong Buy the top 15%. Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. IC is the company's Spearman information coefficient between its past forecasts and the realised returns at the selected horizon; IC-weighted ranking multiplies each forecast by its IC (negative IC counts as zero). Δ is the rating move since the company's previous signal, in rating steps. Each company shows its latest signal, including one from a run still in progress; every signal is rated against the cut-offs above. Quantitative research output, not investment advice.